Residency · Residency · Cardiothoracic Surgery
Esophageal Cancer: Staging, Neoadjuvant Therapy, and Surgical Planning
Overview
Esophageal cancer is the 6th leading cause of cancer death worldwide. Two main histologic types predominate: adenocarcinoma (predominant in Western countries, associated with GERD and Barrett esophagus, arising in the distal esophagus and GEJ) and squamous cell carcinoma (predominant in Asia and Africa, associated with tobacco, alcohol, and caustic injury, typically arising in the mid-esophagus). Overall 5-year survival is approximately 20%, though early detection and multimodal therapy improve outcomes significantly.
TNM Staging (AJCC 8th Edition)
T (Primary Tumor)
Tis denotes high-grade dysplasia or carcinoma in situ. T1a indicates invasion into the lamina propria or muscularis mucosae. T1b indicates invasion into the submucosa. T2 denotes invasion into the muscularis propria. T3 denotes invasion into the adventitia. T4a indicates invasion into the pleura, pericardium, diaphragm, or adjacent peritoneum (resectable). T4b indicates invasion into the aorta, vertebral body, trachea, or other unresectable structures.
N (Regional Lymph Nodes)
N0 indicates no regional lymph node metastasis. N1 denotes 1-2 positive regional nodes. N2 denotes 3-6 positive regional nodes. N3 denotes 7 or more positive regional nodes.
M (Distant Metastasis)
M0 indicates no distant metastasis. M1 indicates distant metastasis, including non-regional lymph nodes.
Stage Groupings and Survival
| Stage | TNM Grouping | 5-Year Survival |
|---|---|---|
| I | T1 N0 M0 | 70-80% |
| II | T2 N0, T1 N1 | 40-50% |
| III | T3 N0-N2, T4a, higher N | 15-25% |
| IV | M1 | < 5% |
Stage Groupings (Simplified)
Stage I (T1 N0) carries approximately 70-80% 5-year survival. Stage II (T2 N0 or T1 N1) carries 40-50%. Stage III (T3 N0-N2, T4a, higher N burden) carries 15-25%. Stage IV (M1) carries less than 5%.
<image>TNM staging diagram for esophageal cancer showing depth of wall invasion (T stages) from mucosa through adventitia</image>
Diagnostic Workup
Endoscopy
Upper endoscopy (EGD) with biopsy is the initial diagnostic procedure, providing assessment of tumor location, length, and degree of obstruction. Barrett esophagus surveillance enables detection of dysplasia and early cancer.
Endoscopic Ultrasound (EUS)
EUS is the most accurate modality for T staging (80-90% accuracy) and assesses depth of invasion through the esophageal wall layers. Regional lymph node evaluation with EUS-guided FNA of suspicious nodes is possible. EUS cannot be performed if the tumor is obstructing and the scope cannot pass. Combined T and N staging accuracy is 75-85%.
PET-CT
PET-CT detects distant metastatic disease with sensitivity of approximately 70% for M staging and identifies occult metastases in 10-20% of patients thought to have locoregional disease. It is useful for both initial staging and response assessment after neoadjuvant therapy. False negatives occur with mucinous tumors and small volume peritoneal disease, while false positives occur with inflammatory conditions.
CT Chest and Abdomen with Contrast
CT provides assessment of local invasion, lymphadenopathy, and distant metastases (liver, lung, adrenal) and complements PET-CT for anatomic detail.
Staging Laparoscopy
Staging laparoscopy is recommended for GEJ and distal esophageal adenocarcinoma (T3-T4 or node-positive), detecting occult peritoneal or liver metastases missed on imaging in 10-15% of patients. Peritoneal washings for cytology are also obtained.
Bronchoscopy
Bronchoscopy is performed for mid to upper esophageal tumors to assess tracheobronchial invasion and is essential when the tumor is in proximity to the airway.
Neoadjuvant Therapy
CROSS Trial (Neoadjuvant Chemoradiation)
The CROSS trial is the landmark phase III trial that compared neoadjuvant carboplatin plus paclitaxel plus 41.4 Gy radiation followed by surgery versus surgery alone in patients with T1N1 or T2-T3 N0-N1 esophageal or GEJ cancer. Median OS was 49.4 months with neoadjuvant therapy versus 24.0 months with surgery alone. R0 resection was achieved in 92% versus 69%. The pathologic complete response (pCR) rate was 29% overall (49% for squamous cell carcinoma, 23% for adenocarcinoma). There was no increase in postoperative mortality. This trial established neoadjuvant chemoradiation as the standard of care for locally advanced esophageal cancer.
Perioperative Chemotherapy (FLOT Regimen)
The FLOT4 trial compared perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) versus ECF/ECX for GEJ and gastric adenocarcinoma. FLOT showed superior OS (median 50 versus 35 months) and is now the preferred perioperative chemotherapy regimen for GEJ adenocarcinoma, administered as 4 cycles neoadjuvant plus 4 cycles adjuvant.
Landmark Neoadjuvant Trials in Esophageal Cancer
| Trial | Regimen | Population | Key Result |
|---|---|---|---|
| CROSS | Carboplatin + paclitaxel + 41.4 Gy → surgery | T1N1 or T2-T3 N0-N1 | Median OS 49.4 vs. 24.0 mo; pCR 29%; R0 92% vs. 69% |
| FLOT4 | Perioperative FLOT (4+4 cycles) | GEJ/gastric adenocarcinoma | Median OS 50 vs. 35 mo; superior to ECF/ECX |
| CheckMate 577 | Adjuvant nivolumab (1 yr) after neoChRT + surgery (non-pCR) | Residual disease post-neoChRT | DFS 22.4 vs. 11.0 mo; FDA-approved |
Neoadjuvant Immunotherapy
CheckMate 648 and KEYNOTE-590 have demonstrated immunotherapy combinations for advanced esophageal cancer. Neoadjuvant immunotherapy plus chemoradiation trials are ongoing (PALACE-1, DANTE). CheckMate 577 studied adjuvant nivolumab after neoadjuvant chemoradiation plus surgery in patients with residual disease (non-pCR). One year of adjuvant nivolumab improved DFS (median 22.4 versus 11.0 months) and is FDA-approved for this indication.
<image>CROSS trial treatment schema showing neoadjuvant chemoradiation regimen followed by esophagectomy, with pathologic response rates for adenocarcinoma and squamous cell carcinoma</image>
Response Assessment After Neoadjuvant Therapy
Repeat CT and PET-CT are obtained after completing neoadjuvant therapy. PET response (decrease in SUV) correlates with pathologic response. EUS has limited accuracy for restaging after chemoradiation because fibrosis mimics residual tumor. Clinical complete response (cCR) does not always equal pathologic complete response, and surgery typically proceeds 6-10 weeks after completing neoadjuvant CRT.
Patient Optimization for Surgery
Nutritional Assessment
Dysphagia and weight loss are extremely common at presentation. Nutritional screening includes BMI, albumin, and weight loss trajectory. Enteral nutrition is preferred, with feeding jejunostomy placement (laparoscopic) if prolonged neoadjuvant therapy is planned, or nasojejunal tube for shorter-term support. Immunonutrition (arginine, omega-3, nucleotides) perioperatively may reduce complications. The target is to minimize weight loss and optimize protein stores before surgery.
Cardiopulmonary Assessment
Esophagectomy is a high-morbidity procedure requiring thorough cardiac and pulmonary evaluation. Pulmonary function testing (FEV1, DLCO) and cardiopulmonary exercise testing (CPET) are obtained, with VO2max greater than 15 mL/kg/min associated with acceptable risk. Smoking cessation for a minimum of 4 weeks preoperatively is required, and prehabilitation with exercise programs and respiratory physiotherapy is recommended.
Comorbidity Optimization
Diabetes management with glycemic control (HbA1c less than 8%), alcohol cessation to reduce withdrawal and hepatic dysfunction risk, and dental evaluation to reduce aspiration pneumonia risk are all important.
Surgical Planning Considerations
Tumor Location and Approach Selection
Cervical esophagus tumors are best treated with definitive chemoradiation, with laryngopharyngoesophagectomy reserved for salvage. Upper and mid-thoracic tumors are managed with a McKeown three-field approach or Ivor Lewis with a high thoracic anastomosis. Distal and GEJ tumors are managed with Ivor Lewis (most common), transhiatal, or extended gastrectomy depending on the Siewert classification: Siewert I (1-5 cm above the GEJ) is treated with esophagectomy, Siewert II (1 cm above to 2 cm below the GEJ) with either esophagectomy or extended gastrectomy, and Siewert III (2-5 cm below the GEJ) with extended gastrectomy preferred.
Siewert Classification of GEJ Tumors
| Type | Location | Preferred Surgical Approach |
|---|---|---|
| Siewert I | 1-5 cm above GEJ | Esophagectomy |
| Siewert II | 1 cm above to 2 cm below GEJ | Esophagectomy or extended gastrectomy |
| Siewert III | 2-5 cm below GEJ | Extended gastrectomy preferred |
Conduit Selection
The gastric conduit is most commonly used, with a reliable blood supply from the right gastroepiploic artery. Colon interposition is used when there has been prior gastric surgery or insufficient gastric length. Jejunal interposition is less common and used for short cervical esophageal defects.
Lymph Node Targets
Adequate lymphadenectomy requires a minimum of 15 lymph nodes for accurate staging. Two-field lymphadenectomy (thoracic plus abdominal) is standard in Western practice. Three-field lymphadenectomy (adding cervical nodes) is practiced primarily in Japan and provides more thorough staging but with higher morbidity.
<image>Siewert classification of gastroesophageal junction tumors (Types I, II, III) with recommended surgical approaches for each type</image>
Clinical Pearls
Staging laparoscopy should be performed for T3/T4 and node-positive GEJ adenocarcinoma — occult peritoneal disease is found in 10-15% and spares patients unnecessary esophagectomy. EUS is the best modality for T staging, but it becomes unreliable after neoadjuvant therapy due to fibrosis. Clinical complete response after neoadjuvant CRT does not mean pathologic complete response — surgery remains indicated in most cases. The CROSS regimen is the most widely adopted neoadjuvant approach for esophageal cancer, while FLOT is preferred specifically for GEJ adenocarcinoma. Nutritional optimization is not optional — malnourished patients have significantly higher morbidity and mortality after esophagectomy. CheckMate 577 established adjuvant nivolumab for patients who do not achieve pCR after neoadjuvant CRT plus surgery. The Siewert classification guides the choice between esophagectomy and gastrectomy for GEJ tumors.
References
- van Hagen P et al. "Preoperative chemoradiotherapy for esophageal or junctional cancer (CROSS)." N Engl J Med. 2012.
- Shapiro J et al. "Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results." Lancet Oncol. 2015.
- Al-Batran SE et al. "Perioperative chemotherapy with FLOT versus ECF/ECX for gastric or GEJ adenocarcinoma (FLOT4-AIO)." Lancet. 2019.
- Kelly RJ et al. "Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (CheckMate 577)." N Engl J Med. 2021.
- Rice TW et al. "8th Edition AJCC/UICC Staging of Esophageal and Esophagogastric Junction Cancers." Ann Surg Oncol. 2017.
- NCCN Clinical Practice Guidelines: Esophageal and Esophagogastric Junction Cancers. Version 2024.
